Needham Says Promising Data Underscore Growth Potential for Jazz Pharma (JAZZ)

On June 3, Needham analyst Ami Fadia reaffirmed a Buy rating on Jazz Pharmaceuticals plc (NASDAQ:JAZZ) and raised the price target slightly from $200 to $202. Fadia’s favorable opinion was based on recent encouraging clinical data updates from the annual American Society of Clinical Oncology (ASCO) 2025 meeting, which strengthen the company’s oncology pipeline.

New data support the role of Zanidatamab (Zani) in bile duct cancer (BTC) and highlight its potential for gastroesophageal adenocarcinoma (GEA). These findings suggest Zani could provide meaningful benefits in both conditions and enhance its commercial outlook.

Needham Says Promising Data Underscore Growth Potential for Jazz Pharma (JAZZ)

A scientist researching the innate and adaptive immune response in a biopharmaceutial laboratory.

Fadia also noted progress with Zepzelca, which is being evaluated as a first-line maintenance treatment for small cell lung cancer (SCLC). Phase 3 results from the ImForte trial, which studies the combination of Lurbinectedin (lurbi) and Atezolizumab (atezo), indicate strong safety and efficacy, reinforcing the likelihood of regulatory approval.

Additionally, updated Phase 2 results for Zani in first-line GEA showed high response rates and improved survival compared to current treatments. In second-line BTC, Zani continues to show substantial survival benefits, outperforming external benchmarks.

Overall, these developments mark steady progress in Jazz’s oncology portfolio. While further validation and regulatory approvals are needed, the latest data support a positive outlook for the stock.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is a biopharmaceutical company focused on developing therapies for oncology and neuroscience.

While we acknowledge the potential of JAZZ as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than JAZZ and that has 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.